1. Biochemistry and Chemical Biology

Mechanism of stepwise electron transfer in six-transmembrane epithelial antigen of the prostate (STEAP) 1 and 2

  1. Kehan Chen
  2. Lie Wang
  3. Jiemin Shen
  4. Ah-Lim Tsai
  5. Ming Zhou  Is a corresponding author
  6. Gang Wu  Is a corresponding author
  1. Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, United States
  2. Division of Hematology-Oncology, Department of Internal Medicine, University of Texas-McGovern Medical School, United States
https://doi.org/10.7554/eLife.88299.3
Share this article
Cite this article
  1. Kehan Chen
  2. Lie Wang
  3. Jiemin Shen
  4. Ah-Lim Tsai
  5. Ming Zhou
  6. Gang Wu
(2023)
Mechanism of stepwise electron transfer in six-transmembrane epithelial antigen of the prostate (STEAP) 1 and 2
eLife 12:RP88299.
https://doi.org/10.7554/eLife.88299.3
  2. Download BibTeX
  3. Download .RIS

eLife assessment

This study provides useful insights into the mechanisms of electron transport in STEAP proteins, consistent with current models. The work strengthens and supports previously published biochemical and structural data, and the experimental results are of solid technical quality. The manuscript will be of interest to colleagues who work on STEAP proteins and related electron transfer systems.

https://doi.org/10.7554/eLife.88299.3.sa0

Abstract

Six transmembrane epithelial antigen of the prostate (STEAP) 1–4 are membrane-embedded hemoproteins that chelate a heme prosthetic group in a transmembrane domain (TMD). STEAP2–4, but not STEAP1, have an intracellular oxidoreductase domain (OxRD) and can mediate cross-membrane electron transfer from NADPH via FAD and heme. However, it is unknown whether STEAP1 can establish a physiologically relevant electron transfer chain. Here, we show that STEAP1 can be reduced by reduced FAD or soluble cytochrome b5 reductase that serves as a surrogate OxRD, providing the first evidence that STEAP1 can support a cross-membrane electron transfer chain. It is not clear whether FAD, which relays electrons from NADPH in OxRD to heme in TMD, remains constantly bound to the STEAPs. We found that FAD reduced by STEAP2 can be utilized by STEAP1, suggesting that FAD is diffusible rather than staying bound to STEAP2. We determined the structure of human STEAP2 in complex with NADP+ and FAD to an overall resolution of 3.2 Å by cryo-electron microscopy and found that the two cofactors bind STEAP2 similarly as in STEAP4, suggesting that a diffusible FAD is a general feature of the electron transfer mechanism in the STEAPs. We also demonstrated that STEAP2 reduces ferric nitrilotriacetic acid (Fe3+-NTA) significantly slower than STEAP1 and proposed that the slower reduction is due to the poor Fe3+-NTA binding to the highly flexible extracellular region in STEAP2. These results establish a solid foundation for understanding the function and mechanisms of the STEAPs.

Introduction

Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) was first discovered owing to its high level of expression in prostate cancer cells (Hubert et al., 1999). Discovery of STEAP2–4 soon followed, and further analyses show that STEAP2–4 have metal ion reductase activities (Grunewald et al., 2012; Ohgami et al., 2006). STEAP3 was identified as a ferrireductase required for iron uptake in erythroid cells (Ohgami et al., 2006; Ohgami et al., 2005). STEAP2–4 are also found overexpressed in many types of cancer cells, suggesting their involvement in cancer initiation or progression (Hubert et al., 1999; Gomes et al., 2013; Rocha et al., 2021).

Each STEAP protein has a transmembrane domain (TMD) which consists of six transmembrane helices (TM), and STEAP2–4, but not STEAP1, also have an N-terminal intracellular oxidoreductase domain (OxRD) (Pick, 2023; Kleven et al., 2015). TMD of the STEAP family of proteins are homologous to membrane-embedded reductases including mammalian NADPH oxidases (NOX) and dual oxidases (DUOX), and bacterial and yeast ferric reductases (Zhang et al., 2013). The structures of NOX and DUOX show that their TMD binds two heme prosthetic groups, each ligated to a pair of conserved histidine residues from TMs 3 and 5; one heme is close to the intracellular side and the other close to the extracellular side of the TMD (Wu et al., 2021; Sun, 2020; Liu et al., 2022; Magnani et al., 2017; Oosterheert et al., 2020). In NOX or DUOX, the OxRD binds both NADPH and FAD, and the cross-membrane electron transfer chain starts with hydride transfer from NADPH to FAD, and then sequentially to the intracellular and extracellular hemes, and finally to the substrate. The structure of STEAP4, on the other hand, shows that only one heme is present in the TMD and it corresponds to the extracellular heme in NOX or DUOX (Oosterheert et al., 2018). In STEAP4, the FAD straddles OxRD and TMD with the isoalloxazine ring of FAD binding at the equivalent position of the intracellular heme in NOX and DUOX and the nucleotide moiety of FAD binding to the OxRD (Figure 1). While this configuration allows electron transfer between FAD and heme, the isoalloxazine ring is too far away from the nicotinamide ring of NADPH to receive hydride. Thus, the isoalloxazine ring of FAD must dissociate from the TMD and move closer to the nicotinamide ring of NADPH for hydride transfer. Although the isoalloxazine ring of FAD must assume different conformations during the redox cycles in STEAPs, its adenosine moiety could stay bound to the OxRD. However, here we show evidence that FAD does not stay tightly bound to the STEAP protein and can become diffusible after its reduction.

Figure 1
Download asset Open asset
The structures of NADPH oxidases (NOX), dual oxidases (DUOX), and six-transmembrane epithelial antigen of the prostate (STEAPs).

The crystal structures of the transmembrane domain (TMD) and oxidoreductase domain (OxRD) of NOX5 (from Cylindrospermum stagnale) are plotted together (PDB codes: TMD, 5o0t; OxRD, 5o0x). The cryo-electron microscopy (cryo-EM) structure of human DUOX1 (PDB code: 7d3f) shows dimeric oligomerization (green and cyan) complexed with DUOX auxiliary protein A1 (DUOXA1, wheat and yellow). The cryo-EM structures of STEAPs are homotrimers (green, cyan, and wheat. PDB codes: STEAP1, 6y9b; STEAP4, 6hcy; STEAP2, 7tai). In DUOX and STEAPs, only one set of cofactors and heme group are shown for clarity. Heme, red; FAD, orange; NADP+, magenta. The lines represent cell membrane (top, extracellular and bottom, intracellular).

STEAP1 has been considered not be able to establish an electron transfer chain due to its lack of an OxRD, however, recent structures of STEAP1 and STEAP4 offer some hints otherwise (Oosterheert et al., 2018; Oosterheert and Gros, 2020). In the STEAP4 structure, the isoalloxazine ring of FAD is coordinated by residues in TMD that are conserved in STEAP1. The structure of STEAP1 aligns well with that the TMD of STEAP4, and although FAD is not present in the STEAP1 structure (Oosterheert and Gros, 2020), we showed previously that purified STEAP1 contains residual FAD, and that FAD binds to STEAP1 with KD of ~32 µM (Kim et al., 2016). Building upon these knowledge, we focused on identifying conditions that allow formation of a transmembrane electron transfer chain in STEAP1. We also determined the structure of human STEAP2, which shows that it has a more flexible substrate binding site compared to STEAP1 and STEAP4.

Results

Reduction of STEAP1 by reduced FAD

We first examined if the heme on STEAP1 can be reduced by FAD. We found that reduced FAD (as FADH-) readily reduces STEAP1, shown by the fast decrease in the Soret absorbance of ferric heme (A413) and the concomitant increase in the Soret absorbance of ferrous heme (A427) (Figure 2A). The time course of A427 increase is biphasic. The fast phase has a rate constant of 7.7 s–1 and accounts for 60% of the total change at A427, and the slow phase, 0.67 s–1 and 40% (Figure 2B). The rate constants of both phases exhibit dependence on [FADH-]. The Vmax and KM are estimated 12 s–1 and 4.7 μM for the fast phase, and the parameters are estimated 0.9 s–1 and 2.7 μM for the slow phase (Figure 2B, inset).

Figure 2 with 1 supplement see all
Download asset Open asset
Reduction of the heme on six-transmembrane epithelial antigen of the prostate 1 (STEAP1).

(A) Rapid-scan reaction of 1.1 μM STEAP1 with 4.5 μM reduced FAD (FADH-); the spectral change was monitored for 20 s. (B) The time course of A427 (black), the Soret absorbance of ferrous heme, was extracted from the rapid-scan data. Red: biphasic exponential fit with rate constants kobs of 7.7 (±0.30) and 0.67 (±0.034) s–1, respectively (n=3). The percentage of each phase is 60% and 40%, respectively. Inset, the dependence of rate constants on [FADH-]. Dot, the fast phase; triangle, the slow phase. Lines, fit with equation kobs = Vmax* [FADH-]/(KM + [FADH-]). (C) The spectral changes in the reaction of a mixture of 1.1 μM STEAP2 and 0.9 μM STEAP1 (plus 2.2 μM FAD) with 60 μM NADPH; the spectral change was monitored for 1 hr. The direction of the spectral changes is indicated by the arrows. Blue, the spectrum captured at the start of the reaction; red, the spectrum after 1 hr reaction. Inset, the resolved spectral species by deconvolution and the conversion rate constant. Black, ferric STEAP and red, ferrous STEAP.

In STEAP4 structure, a phenylalanine side chain (Phe359) is positioned between the isoalloxazine ring of FAD and the heme and is thought to mediate electron transfer from FAD to heme (Oosterheert et al., 2018). In STEAP1–3, the equivalent residue is a leucine, Leu230 in STEAP1 (Figure 2—figure supplement 1A). To examine if Leu230 is involved in electron transfer, we expressed and purified the L230G STEAP1 mutant. The UV-Vis spectrum of L230G STEAP1 is identical to that of the wild-type (WT) STEAP1 (Figure 2—figure supplement 1B), indicating that the mutation does not perturb heme binding. When FADH- was added to L230G STEAP1, biphasic reduction of heme was observed and the kobs’s showed dependence on [FADH-]. The Vmax and KM are estimated 2 s–1 and 3.6 μM for the fast phase, and the parameters are estimated 0.16 s–1 and 1.1 μM for the slow phase (Figure 2—figure supplement 1C). These results indicate that the heme in L230G STEAP1 is reduced by FADH- more than five times slower than in WT STEAP1, suggesting that the side chain of Leu230 is involved in mediating electron transfer between FAD and heme in STEAPs.

Reduction of STEAP1 by cytochrome b5 reductase

We proceeded to test whether the heme on STEAP1 can be reduced by cytochrome b5 reductase (b5R). b5R catalyzes the reduction of a tightly bound FAD by NADH and is known to reduce the heme on cytochrome b5 (Hall et al., 2022; Shen et al., 2022). Under anaerobic conditions, STEAP1 does not react with NADH but in the presence of both b5R and NADH, the A427 absorbance increases indicating reduction of the heme on STEAP1 (Figure 3—figure supplement 1A). Using rapid-scan stopped-flow method, we captured the kinetics of the reactions when STEAP1 pre-incubated with b5R was mixed with NADH (Figure 3A). The reduction of STEAP1 is clearly indicated by the shift of Soret peak (A413 to A427) and the split and increase of the α and β bands at 560 nm and 530 nm, respectively (Figure 3A). Three spectral species, A, B, and C, are resolved with rate constants of 177.9 (±35.3) s–1 (A to B) and 0.13 (±0.006) s–1 (B to C), respectively (Figure 3A, inset). Spectral species A corresponds to ferric STEAP1 plus oxidized b5R while species C is ferrous STEAP1 with fully reduced b5R. A spectral intermediate species B can be identified with decreased absorbance in 420–500 nm range but little or no change in the Soret range when compared to A (Figure 3A, inset), indicating that the intermediate B contains partially reduced b5R and a ferric heme. The resolution of intermediate B is due to fast FAD reduction in b5R by NADH without significant STEAP1 reduction. The B to C conversion reflects electron transfer from reduced b5R to STEAP1 (Figure 3A), indicating that STEAP1 can form an electron transfer chain with b5R.

Figure 3 with 2 supplements see all
Download asset Open asset
Reduction of six-transmembrane epithelial antigen of the prostate 1 (STEAP1) by cytochrome b5 reductase (b5R).

(A) The rapid-scan reaction of 1.5 μM STEAP1 and 1.5 μM cytochrome b5R with 10 μM NADH; the spectral change was monitored for 20 s. The arrows indicate the direction of the spectral change. Inset: the resolved spectral species and the conversion rate constants. Black, ferric STEAP1 with b5R, red, a spectral intermediate, and green, ferrous STEAP1 with fully reduced b5R. (B) L230G STEAP1 and b5R were reacted with 10 μM NADH; the spectral change was monitored for 50 s. The direction of spectral change is indicated by the arrows. Inset, the resolved spectral species by deconvolution and the rate constants. Inset: black, ferric L230G STEAP1 with b5R, red, a spectral intermediate, and green, ferrous L230G STEAP1 with fully reduced b5R.

We next examined whether b5R forms a complex with STEAP1. Using bio-layer interferometry (BLI) assay, we measured the affinity between b5R and STEAP1 and found that b5R binds STEAP1 with a KD of ~5.9 µM (Figure 3—figure supplement 2). We noticed that the fits to the association and dissociation profiles in BLI assay are rather poor at high concentrations of b5R and this is likely due to non-specific interactions between STEAP1 with b5R. Nonetheless, our BLI data demonstrates that b5R can dock onto STEAP1 to establish an electron transfer chain.

We also examined reduction of L230G STEAP1 by NADH and b5R (Figure 3B). Three spectral species, A, B, and C, are resolved, and the rate constants are 78.8 (±22.6) s–1 (A to B) and 0.02 (±0.01) s–1 (B to C) (Figure 3B, inset). Species A corresponds to ferric L230G STEAP1 with oxidized b5R while species C represents ferrous L230G STEAP1 with fully reduced b5R (Figure 3B, inset). As in WT STEAP1, the fast reduction of b5R by NADH leads to the resolution of spectral intermediate B, which has decreased absorbance between 420 nm and 500 nm but approximately the same Soret absorbance compared to A (Figure 3B, inset). On the other hand, the rate constant from B to C, which is electron transfer rate from reduced b5R to the heme, is significantly slower in L230G STEAP1 than in WT STEAP1 (Figure 3B, inset), suggesting that Leu230 is involved in the electron transfer from b5R to STEAP1.

Purification and characterization of STEAP2

While structures of full-length STEAP1 and STEAP4 have been determined by cryo-electron microscopy (cryo-EM) (Oosterheert et al., 2018; Oosterheert and Gros, 2020), those of full-length STEAP2 and STEAP3 remain unresolved. We expressed and purified human STEAP2, which elutes as a single peak in size exclusion chromatography and the elution volume is consistent with STEAP2 being a homotrimer (Figure 4A). A prominent heme absorption peak is present in the purified STEAP2, and the heme content typically ranges from 70% to 90%. FAD is also detected in the purified STEAP2, however, at a level typically lower than 20% based on the fluorescence of FAD released from denatured STEAP2. No NADP(H) is detected in the purified STEAP2, suggesting that its association with STEAP2 is more transient than either heme or FAD.

Figure 4 with 1 supplement see all
Download asset Open asset
Characterization of purified human six-transmembrane epithelial antigen of the prostate 2 (hSTEAP2).

(A) SDS-PAGE analysis and size exclusion chromatography of purified hSTEAP2. The UV-Vis (B) and magnetic circular dichroism (MCD) (C) spectra of hSTEAP2 are plotted with absorbance in mM–1 cm–1 and MCD in M–1 cm–1 Tesla–1, respectively. STEAP2 was purified in the ferric state (black) and the ferrous STEAP2(red) was prepared by dithionite reduction.

The UV-Vis spectra of STEAP2 heme are identical to those of STEAP1 heme. Ferric STEAP2 shows a Soret band at 413 nm and a broad Q band centered around 550 nm while the Soret band in ferrous STEAP2 shifts to 427 nm and the α and β bands are resolved at 560 nm and 532 nm, respectively (Figure 4B). We further characterized the heme using magnetic circular dichroism (MCD) spectroscopy. The MCD spectrum of ferric STEAP2 shows strong Soret signals between 404 nm and 419 nm and no high-spin charge-transfer signal at wavelength above 600 nm while ferrous STEAP2 shows a much weaker Soret band but a very strong α band from 554 nm to 562 nm (Figure 4C), consistent with the intense A-term Faraday effect of a typical low-spin b-type heme. Combined, the spectroscopic data indicates a bis-imidazole ligated low-spin heme in both redox states of STEAP2, consistent with a role in mediating electron transfer.

We monitored the spectral changes in STEAP2 in the reaction with NADPH. STEAP2 was pre-incubated with equal molar amount of FAD and reacted anaerobically with NADPH (Figure 4—figure supplement 1A). In this reaction, the Soret absorbance of heme shifts from that of ferric state (A413) to that of ferrous heme (A427) while the α and β absorptions split into well-resolved peaks at 560 nm and 532 nm, respectively, indicating the reduction of heme (Figure 4—figure supplement 1A). Two spectral species are resolved with a transition rate constant of 1.2 (±0.2)×10–3 s–1 (A to B). Spectral species A corresponds to ferric STEAP2 plus FAD and spectral species B represents ferrous STEAP2 with reduced FAD, respectively (Figure 4—figure supplement 1A, inset). Under the current experimental conditions, no intermediate with reduced FAD and ferric heme is resolved, suggesting that the oxidation of FAD by heme is significantly faster than its reduction by NADPH.

STEAP1 reduction by STEAP2

Following the characterization of STEAP2, we investigated whether the reduced FAD produced in STEAP2 is accessible to STEAP1. We prepared an anaerobic mixture of STEAP2 (pre-incubated with equal molar of FAD) and STEAP1 and then added NADPH (Figure 2C). In this reaction, the Soret absorbance of heme shifts from 413 nm to 427 nm and finally a narrow peak is observed at 427 nm with no shoulder at 413 nm (Figure 2C). This result indicates that the heme on both STEAP1 and STEAP2 is fully reduced since both isozymes have Soret absorbance at 413 nm in the ferric state and at 427 nm in the ferrous state. Two spectral species are resolved from the reaction of the STEAP mixture with NADPH, corresponding to ferric STEAP plus FAD and ferrous STEAP with reduced FAD, with a rate constant of 5.5×10–4 s–1 (Figure 2C, inset). On the other hand, in the absence of STEAP2, only a small fraction of STEAP1 is reduced (Figure 3—figure supplement 1B), which may come from non-enzymatic reduction of FAD by NADPH. Thus, the heme on STEAP1 can be reduced by NADPH in the presence of STEAP2, via the reduced FAD produced in the OxRD of STEAP2. This data suggests that the reduced FAD becomes diffusible and quickly finds its binding pocket in the TMD of STEAP1. Under the current experimental conditions, the rate-limiting step seems to be the production of reduced FAD in the OxRD of STEAP2. Moreover, we cannot resolve the difference between diffusion of reduced FAD from STEAP2 to STEAP1 versus repositioning of reduced FAD from the OxRD to TMD in STEAP2.

Fe3+-NTA reduction by STEAP1 and STEAP2

Our ability to produce reduced STEAP1 and STEAP2 allows measurement of the electron transfer step between the heme and a substrate. When reduced STEAP1 was mixed with ferric nitrilotriacetic acid (Fe3+-NTA), the A427 absorbance decreased, indicating that the ferrous heme is oxidized by Fe3+-NTA. The time courses of A427 show biphasic kinetics with a fast phase accounting for 85% of the total absorbance change and a slow phase accounting for 15% (Figure 5A). Similar biphasic kinetics was previously observed in the reactions of ferrous STEAP1 with Fe3+-EDTA or Fe3+-citrate (Kim et al., 2016). We speculate that there are two STEAP1 populations in terms of the conformation of the substrate binding site or geometry of the heme, or both. The kon and koff rate constants of Fe3+-NTA are estimated based on the kobs vs. [Fe3+-NTA] (Figure 5B) and the KD values of Fe3+-NTA for the two populations of STEAP1 are calculated, 50 μM and 26.3 μM, for the fast and slow phase, respectively (Table 1). The KD values of Fe3+-NTA are similar to those of Fe3+-EDTA or Fe3+-citrate (Table 1).

Figure 5
Download asset Open asset
Reduction of ferric nitrilotriacetic acid (Fe3+-NTA) by ferrous six-transmembrane epithelial antigen of the prostate 1 (STEAP1) and STEAP2.

(A) The time courses of A427 in the reactions of 1.1 μM ferrous STEAP1 with 25 (black), 75 (red), 125 (green), 175 (yellow), and 175 μM Fe3+-NTA (blue). The rate constants, kobs, are estimated by biphasic exponential fit to the time courses. One of such fits is shown by the black line. (B) Dependence of the rate constants kobs on [Fe3+-NTA]. Circles, kobs of the fast phase of the A427 time courses; triangles, kobs of the slow phase. (C) The time courses of A427 in the reactions of 1.1 μM ferrous STEAP2 with 75 (black), 125 (red), and 175 μM Fe3+-NTA (green). The time courses in the initial 2 s of the reactions are fitted with a biphasic exponential function, and one such fit is shown by the black line. (D) The rate constants estimated for the initial 2 s, kobs, are plotted versus [Fe3+-NTA]. Circles, kobs of the fast phase of the A427 time courses; triangles, kobs of the slow phase. At reaction time longer than 2 s, the time courses in (C) show more complicated kinetics and no clear dependence on [Fe3+-NTA].

Table 1
The rate constants of the reduction of ferric substrates by ferrous six-transmembrane epithelial antigen of the prostate 1 (STEAP1) and STEAP2.
SubstratesFirst phaseSecond phase
kon, M–1 s–1/koff, s–1KD, μM*kon, M–1 s–1/koff, s–1KD, μM*
STEAP1†Fe3+-EDTA2.7×105/4.817.84.0×104/1.435
STEAP1†Fe3+-citrate1.6×105/15.597––
STEAP1 ‡Fe3+-NTA1.5×105/7.5507.6×103/0.226.3
STEAP2 ‡, §Fe3+-NTA1.1×104/2.22003.5×103/0.385.7
  1. *

    : KD = koff/kon.

  2. †

    From Kim, K. et al, Biochemistry (2016) 55, 6673–6684.

  3. ‡

    This study.

  4. §

    The third phase is not included.

The oxidation of ferrous STEAP2 by Fe3+-NTA is significantly slower than that of STEAP1 and the time courses of A427 show more than two phases (Figure 5C), suggesting more heterogeneity in the substrate binding site or heme geometry. The ΔA427 in the initial 2 s accounts for about half of the total A427 decrease and the time courses in the initial 2 s can be fitted with a biphasic exponential decay function (Figure 5C). The rate constants kobs of the two phases show weak dependence on [Fe3+-NTA] (Figure 5D). The kon and koff rate constants of Fe3+-NTA binding are estimated based on the kobs vs. [Fe3+-NTA] plot (Figure 5D) and the KD’s of Fe3+-NTA are calculated, 200 μM and 85.7 μM, for the fast and slow phases, respectively (Table 1). After the initial 2 s, the time courses of A427 become slower with varying complicated shapes and have no clear dependence on [Fe3+-NTA] (Figure 5D).

Cryo-EM structure of STEAP2

To understand the structural basis for the slow Fe3+-NTA reduction by STEAP2 compared to STEAP1, we determined the structure of STEAP2 in the presence of NADP+ and FAD using cryo-EM. The cryo-EM data collection, refinement, and validation statistics are summarized in Table 2. The quality of density map is sufficient to build all the major structural elements of STEAP2 de novo with an overall resolution of 3.2 Å (Figure 6—figure supplement 1, Figure 6—figure supplement 2). The N-terminal residues 1–27, C-terminal residues 470–490, and residues 332–353 (loop between TM3 and -4) are not resolved in our EM map, likely due to high degree of flexibility (Figure 6D). Similar to the structure of STEAP4, STEAP2 has a domain-swapped homotrimer structure, where the OxRD of one protomer interacts with the TMD of a neighboring protomer (Figure 6A and B). Overall, the structure of STEAP2 is very similar to that of STEAP4 with a root mean squared distance of 0.8 Å (Cα) (Oosterheert et al., 2018). In STEAP4, the residues corresponding to 332–353 in STEAP2 form a well-defined extracellular loop adjacent to the putative substrate binding site. The high flexibility of these residues in STEAP2 may lead to poor binding of Fe3+-NTA and its slow reduction by STEAP2.

Figure 6 with 2 supplements see all
Download asset Open asset
Cryo-electron microscopy (cryo-EM) structure of six-transmembrane epithelial antigen of the prostate 2 (STEAP2).

The sharpened density map (A) and cartoon presentation (B) for STEAP2 homotrimer. Top, the side view of STEAP2 homotrimer, and the gray bar represents the membrane; ‘in’, the intracellular side and ‘out’, the extracellular side. Bottom, the top view of STEAP2 homotrimer from the extracellular side. (C) The structure of one STEAP2 protomer (cartoon) with the prosthetic group heme and the cofactors FAD and NADP+ (sticks). Left, side view and right, top view from the extracellular side. (D) The topographic representation of the secondary structural elements. The α helices and β strands are represented by bars and arrows respectively. Dashed lines represent the unresolved segments. (E) The schematic representation of the spatial relationship of NADP+, FAD, and heme, shown as sticks. Trp152 and Leu371 are also shown as sticks. Transmembrane domain (TMD) is represented as the outline with gray shade and the oxidoreductase domain (OxRD) with pink shade.

Table 2
The data collection, refinement, and validation statistics of six-transmembrane epithelial antigen of the prostate 2 (STEAP2) cryo-electron microscopy (cryo-EM).
Data collection and processing
MagnificationFEI Titan Krios
Voltage (kV)300
Electron exposure (e– Å–2)50
Defocus range (μm)–0.8 to –2.5
Pixel size (Å)1.08
Symmetry imposedC3
Number of initial particle images4,210,570
Number of final particle images117,053
Map resolution (Å)3.16
FSC threshold0.143
Map resolution range (Å)3.2
Refinement
Initial model usedPDB 6hcy
Model resolution (Å)3.2
FSC threshold0.5
Map sharpening B factor (Å2)–100
Model composition
 Non-hydrogen atoms11,109
 Protein residues1260
 Ligands18
B factors (Å2)
 Protein41.92
 Ligand32.76
R.m.s. deviations
 Bond lengths (Å)0.003
 Bond angles (°)0.567
Validation
 MolProbity score1.6
 Clashscore10.54
 Poor rotamers (%)0.09
Ramachandran plot
 Favored (%)97.8
 Allowed (%)2.2
 Disallowed (%)0

Heme, FAD, and NADP+ are unambiguously resolved in the density map (Figure 6C and Figure 6—figure supplement 1). The FAD molecule adopts an extended conformation as observed in STEAP4 (Oosterheert et al., 2018). The isoalloxazine ring buries deep in the TMD while the adenine ring of FAD forms a stacking interaction with Trp152 from the OxRD. The ribityl and pyrophosphate in FAD also interacts with residues on TMD. The isoalloxazine ring is ~10 Å away (edge-to-edge) from the heme and the side chain of Leu371 protrudes approximately midway in between (Figure 6E,). Like L230 in STEAP1 (Figure 2—figure supplement 1A), Leu371 may mediate electron transfer in STEAP2. The distance of the isoalloxazine ring of FAD to the nearest nicotinamide ring of NADP+ is ~19 Å (Figure 6E), which is too long for direct hydride transfer. We also found densities that likely correspond to phospholipid and cholesterol molecules. A 1-palmitroyl-2-oleoyl-glycero-3-phosphocholine (POPC) molecule was built between the TMDs of two neighboring protomers, and two cholesterol molecules were built on the periphery of each TMD (Figure 6—figure supplement 1). These tightly bound lipid molecules may have relevant structural and functional roles in STEAP2.

Reduction of STEAP2 by reduced FAD

We measured reduction STEAP2 by reduced FAD in the absence of NADPH. Reacting with 4.5 μM reduced FAD (FADH-), ferric STEAP2 is reduced in biphasic kinetics with rates of 2.9 (±0.80) s–1 (16%) and 6.9 (±0.33)×10–2 s–1 (84%), respectively (Figure 4—figure supplement 1B). The reduction of STEAP2 by reduced FAD is significantly slower than that of STEAP1, and we attribute this to the presence of OxRD in STEAP2, which binds to the adenosine moiety of FAD but obstructs entrance of the isoalloxazine ring of reduced FAD into the TMD.

Discussion

In this study, we demonstrate that STEAP1 is reduced by reduced FAD, either supplied directly or produced in the OxRD of STEAP2. We also show that b5R can reduce STEAP1 in the presence of NADH. Thus, STEAP1 may partner with various flavin-dependent reductases to establish an electron transfer chain from either NADH or NADPH to the extracellular side. These discoveries will facilitate our understanding of the physiological functions of STEAP1.

Purified STEAP2 has low levels of bound FAD, indicating that the FAD cofactor is not tightly bound as observed in other flavin reductases such as b5R or P450 reductase. In the structure of STEAP2, we captured the bound FAD in a conformation suitable for transferring electrons to heme, and the structure is similar to that of STEAP4 (Oosterheert et al., 2018). However, the structure of STEAP2 with the bound FAD in position to receive electrons from NADPH remains unresolved. Reduction of STEAP1 in the presence of STEAP2 provides the first evidence that the bound FAD may dissociate from STEAP2 after receiving electrons from NADPH. We propose that FAD first binds to OxRD of STEAP2 in a folded conformation with its isoalloxazine ring aligned with NADPH for hydride transfer. After receiving electrons from NADPH, reduced FAD may either dissociate from the OxRD and can be utilized by STEAP2 or STEAP1 nearby or stays partially bound to the OxRD and changes into an extended conformation with the isoalloxazine ring inserted deeply into the TMD (Figure 7). A ‘diffusible’ FAD or an FAD that switches between the folded and extended conformations will inevitably limit the rate of the overall electron transfer from NADPH to the extracellular side and is consistent with the kinetics data presented in Figure 2C and Figure 4—figure supplement 1A. This mechanism is different from the electron transfer chains found in the closely related NOX or DUOX enzymes, in which the FAD likely stays bound to the OxRD and thus suitable for rapid transfer of electrons from NADPH to the extracellular side. Moreover, the mechanism of regulating the activities of STEAPs in vivo must be very different from those in NOX or DUOX (Bedard and Krause, 2007) and warrants further investigation.

Figure 7
Download asset Open asset
Electron transfer in six-transmembrane epithelial antigen of the prostate 1 (STEAP1) and STEAP2.

NADPH (blue) and FAD (orange) bind to the oxidoreductase domain (OxRD) in STEAP2 (A, olive shade) with the nicotinamide ring of NADPH aligned with the isoalloxazine ring of FAD for hydride transfer (B). The reduced FAD adopts the extended conformation with its isoalloxazine ring bound deep in the transmembrane domain (TMD) of STEAP2 (C, teal shade) or dissociates from the OxRD to bind STEAP1 (D → E, cyan shade) and transfers electrons to heme (salmon). NADP(H) and FAD(H2) are cofactors that associate with and dissociate from the STEAP protein in each redox cycle while the heme, as a prosthetic group, stays bound to the protein. Cytochrome b5 reductase (F, sand shade) docks on STEAP1 from the intracellular side, forming a complex for electron transfer (G). The FAD-to-heme electron transfer in STEAP is likely mediated through a bulky side chain (purple), Leu230 in STEAP1 and Leu371 in STEAP2, respectively.

We demonstrate that STEAP1 can establish electron transfer chain with b5R, which does not release FAD. We also show that b5R reduces STEAP1 from the intracellular side and it can form a complex with STEAP1 (Figure 7). These results indicate that b5R can serve as a surrogate OxRD to complete the electron transfer chain. However, further analysis is required to establish whether STEAP1 pairs with b5R or other FAD reductase in vivo.

We are able to measure the rate of electron transfer from heme to a ferric substrate, and we found that STEAP2 reduces Fe3+-NTA significantly slower than STEAP1. The more complex time course of heme oxidation also suggests a high level of heterogeneity in either the substrate binding pocket or the heme geometry in STEAP2. In the cryo-EM structure of STEAP2, residues 332–353 between TM3 and 4 are unresolved, likely due to high flexibility in this region, while in the structures of STEAP1 and STEAP4, the corresponding residues form a well-defined extracellular loop adjacent to the putative substrate binding site (Oosterheert et al., 2018; Oosterheert and Gros, 2020). These differences suggest that STEAP2 has different substrates from STEAP4.

Materials and methods

Materials

4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 5-aminolevulinic acid (5-ALA), isopropyl β-D-1-thiogalactopyranoside, phenylmethanesulfonyl fluoride, Fe(NO3)3, hemin chloride, dithionite, POPC, NTA, 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC), and N-hydroxysulfosuccinimide (Sulfo-NHS) were from Sigma-Aldrich (St. Louis, MO, USA). Lauryl maltose neopentyl glycol (LMNG) and glyco-diosgenin (GDN) were from Anatrace (Maumee, OH, USA).

Protein expression and purification

Request a detailed protocol

The human STEAP2 gene (NCBI accession number AAN04080.1) was codon optimized and cloned into a modified pFastBac Dual expression vector for production of baculovirus according to the Bac-to-Bac method (Thermo Fisher Scientific, Waltham, MA, USA). P3 viruses were used to infect High Five (Trichoplusia ni) or Sf9 (Spodoptera frugiperda) insect cells at a density of ~3 × 106 cells mL–1 in the media including 0.5 mM 5-ALA, 10 µM FeCl3, and 5 µM hemin chloride. Infected cells were grown at 27 °C for 48–60 hr before harvest. Cell membranes were prepared using a hypotonic/hypertonic wash protocol as previously described (Bai et al., 2015). Purified cell membrane pellets were then flash-frozen in liquid nitrogen for further use.

Purified membranes were thawed and homogenized in 20 mM HEPES, pH 7.5 buffer containing 150 mM NaCl, and then solubilized with 1.5% (wt/vol) LMNG at 4 °C for 2 hr. After solubilization, cell debris was removed by ultracentrifugation (55,000×g for 45 min at 4 °C), and hSTEAP2 was purified from the supernatant using cobalt-based Talon affinity resin (Clontech, Mountain View, CA, USA). The C-terminal His6-tag was cleaved with tobacco etch virus (TEV) protease at room temperature for 30 min. The protein was concentrated to around 5 mg mL–1 using an Amicon spin concentrator with a 100 kDa cut-off (Millipore, Burlington, MA, USA), and then loaded onto an SRT-3C SEC-300 size exclusion column (Sepax Technologies, Newark, DE, USA) equilibrated with 20 mM HEPES buffer containing 150 mM NaCl and 0.01% (wt/vol) LMNG. For the sample used in the cryo-EM structural studies, the size exclusion column was equilibrated with 20 mM HEPES buffer containing 150 mM NaCl and 0.02% GDN.

Rabbit STEAP1 (NCBI accession number NP_001164745.1) was expressed and purified following the method published previously (Kim et al., 2016). The L230G STEAP1 mutation was introduced by the QuikChange method (Stratagene, CA, USA) using the primers:

  • forward, 5’- CGTGGGACTGGCTATCGGCGCTTTGCTGGCTGTGAC-3’;

  • reverse, 5’- GTCACAGCCAGCAAAGCGCCGATAGCCAGTCCCACG-3’.

The cDNA of mouse cytochrome b5R (UniProt Q3TDX8, soluble form, residues 24–301) was subcloned into a pET vector which appends a polyhistidine tag and a TEV protease site to the N-terminus of the overexpressed protein. The expression of b5R followed the previous protocol (Shen et al., 2020) and the cell media was supplemented with 100 μM FAD.

Electronic absorption and MCD spectroscopy

Request a detailed protocol

UV-Vis spectra of STEAP2 were recorded using a HP8453 diode-array spectrophotometer (Hewlett-Packard, Palo Alto, CA, USA). The extinction coefficient of the heme was determined by pyridine hemochrome assay as published previously (Kim et al., 2016). MCD spectra of STEAP2 were recorded with a Jasco J-815 CD spectropolarimeter (Tokyo, Japan) equipped with an Olis permanent magnet (Bogart, GA, USA). The parameters for MCD measurements are spectral bandwidth, 5 nm; time constant, 0.5 s; scan speed, 200 nm min–1. Each MCD spectrum is an average of 12 repetitive scans and the signal intensity is expressed in units of M–1 cm–1 Tesla–1.

Cryo-EM structure determination of STEAP2

Request a detailed protocol

Quantifoil R1.2/1.3 Cu grids were glow-discharged in air for 15 s at 10 mA in a plasma cleaner (PELCO EasiGlow, Ted Pella, Inc, Redding, CA, USA). Glow-discharged grids were prepared using Thermo Fisher Vitrobot Mark IV. Concentrated hSTEAP2 in the presence of FAD and NADP+ (3.5 μL) was applied to each glow-discharged grid. After blotted with filter paper (Ted Pella, Inc) for 4.0 s, the grids were plunged into liquid ethane cooled with liquid nitrogen. A total of 7509 micrograph stacks were collected using SerialEM (Mastronarde, 2005; Schorb et al., 2019) on a Titan Krios electron microscope (Thermo Fisher) at 300 kV with a Quantum energy filter (Gatan, Pleasanton, CA, USA), at a nominal magnification of ×105,000 and with defocus values of −2.5 μm to −0.8 μm. A K3 Summit direct electron detector (Gatan) was paired with the microscope. Each stack was collected in the super-resolution mode with an exposing time of 0.175 s per frame for a total of 50 frames. The dose was about 50 e− Å−2 for each stack. The stacks were motion-corrected with MotionCor2 (Zheng et al., 2017) and binned (2×2) so that the pixel size was 1.08 Å. Dose weighting (Grant and Grigorieff, 2015) was performed during motion correction, and the defocus values were estimated with Gctf (Zhang, 2016).

A total of 4,210,570 particles were automatically picked (RELION 3.1) (Kimanius et al., 2016; Scheres, 2012; Scheres, 2015) from the motion-corrected images and imported into cryoSPARC (Punjani et al., 2017). After two rounds of two-dimensional classification, a total of 91 classes containing 1,031,895 particles were selected. A subset of 12 classes containing 117,053 particles were selected for ab initio three-dimensional reconstruction, producing one good class with recognizable structural features and three bad classes with no distinct structural features. Both the good and bad classes were used as references in the heterogeneous refinement (cryoSPARC) and yielded a good class at 4.10 Å from 305,849 particles. Non-uniform refinement (cryoSPARC) was then performed with C3 symmetry and an adaptive solvent mask, producing a map with an overall resolution of 3.16 Å. Resolutions were estimated using the gold-standard Fourier shell correlation with a 0.143 cut-off (Rosenthal and Henderson, 2003) and high-resolution noise substitution (Chen et al., 2013). Local resolution was estimated using ResMap (Kucukelbir et al., 2014).

The structural model of STEAP2 was built based on the cryo-EM structure of STEAP4 (PDB ID: 6HCY) (Oosterheert et al., 2018), and the side chains were adjusted based on the density map. Model building was conducted in Coot (Emsley et al., 2010). Structural refinements were carried out in PHENIX in real space with secondary structure and geometry restraints (Adams et al., 2010). The EMRinger Score was calculated as described previously (Barad et al., 2015).

STEAP reduction by NADPH

Request a detailed protocol

STEAP2, 2.3 μM, or a mixture of 1.1 μM STEAP2 and 0.9 μM STEAP1, was pre-incubated with 2.5 μM and 2.2 μM FAD in a tonometer, respectively. The solutions were made anaerobic by 5 anaerobic cycles, each with 30 s vacuum followed by argon sparging for 4.5 min. The stock solution of NADPH was made anaerobic by N2 sparging. Anaerobic NADPH solution was injected into the anaerobic STEAP solution using an airtight syringe and the spectral changes were monitored at room temperature using the HP 8453 spectrophotometer. The spectral changes were deconvoluted using the Pro-Kineticist program coming with the stopped-flow machine (see below).

Stopped-flow experiments

Request a detailed protocol

To measure the electron transfer rate from ferrous STEAP to ferric nitrilotriacetic acid (Fe3+-NTA) substrate, anaerobic STEAP was first titrated to the ferrous state using dithionite and then reacted with Fe3+-NTA on an Applied Photophysics model SX-18MV stopped-flow machine (Leatherhead, UK), which was placed in a COY anaerobic chamber (Grass Lake, MI, USA). The time course of A427, which reflects the oxidation of ferrous STEAP, was followed. Fe3+-NTA was prepared with ferric nitrate and NTA based on a ratio of [Fe3+]:[NTA]=1:4. The rate constants of the redox reactions, kobs, were obtained by fitting the time courses using a monophasic or a multiphasic exponential function. The second-order kon rate constants of Fe3+-NTA to the STEAP protein were estimated from the slopes of the linear fits to the kobs vs. [Fe3+-NTA] plots. On the other hand, the koff rate constants were estimated based on the intercepts on ordinate of the linear fits.

The anaerobic protein mixture of STEAP1 and b5R was reacted with NADH and the spectral changes were monitored using a rapid-scan diode-array accessory with the stopped-flow machine. In the reaction of STEAPs with pre-reduced FAD, FAD in 20 mM HEPES, pH 7.5 containing 150 mM NaCl and 0.1% LMNG was titrated anaerobically with dithionite. Most of the reduced FAD (FADH2) was likely in its ionized form FADH- due to its pKa = 6.7. Part of the reduced FAD was re-oxidized due to the very negative potential of the FAD/FADH- pair, and the absorbance of FAD was subtracted as the background. The spectral changes were deconvoluted using the Pro-Kineticist program coming with the stopped-flow machine.

Octet BLI

Request a detailed protocol

BLI assays were performed at 30°C under constant shaking at 1000 rpm using an Octet system (FortéBio, Fremont, CA, USA). STEAP1 was immobilized on amine reactive second-generation biosensors (Sartorius, Göttingen, Germany). The biosensor tips were activated for 5 min in EDC and 10 mM Sulfo-NHS before being loaded with STEAP1 at a concentration of 1 µg mL–1 for 10 min. The tips were then quenched in 1 M ethanolamine (pH 8.5) for 5 min and equilibrated in 20 mM HEPES, pH 7.5 containing 150 mM NaCl, 0.1% LMNG, and 0.1% BSA to reduce non-specific binding. The tips were then transferred into wells containing various concentration of b5R, 20, 10, 5, 2.5, 1.3, and 0.6 µM, for association and then back to the equilibration wells for dissociation. The binding curves were aligned and corrected with the channel with no analyst protein. The association and dissociation phases were fitted with a monophasic exponential function. The equilibrium responses (Req) in the association incubation were plotted against [b5R] and fitted with a dose-response function to calculate the dissociation constant KD of STEAP/b5R complex.

Data availability

The EM data and fitted model of human STEAP2 are deposited in the Electron Microscopy Data Bank (access code: EMD-25775): https://www.ebi.ac.uk/emdb/EMD-25775 and the RCSB Protein Data Bank (access code: 7TAI): https://www.rcsb.org/structure/7TAI. A repository of kinetics data (source data files for Figure 2 - Figure 5) has been made in Dryad: doi:10.5061/dryad.00000008r. The plasmids for protein expression are available upon request, please contact mzhou@bcm.edu or gang.wu@uth.tmc.edu.

The following data sets were generated
    1. Wu G
    (2023) Dryad Digital Repository
    Kinetics of the redox reactions in STEAP1 and STEAP2.
    https://doi.org/10.5061/dryad.00000008r
    1. Wang L
    2. Chen KH
    3. Zhou M
    (2023) EMDataBank
    ID EMD-25775. Structure of STEAP2 in complex with ligands.
    https://www.ebi.ac.uk/emdb/EMD-25775
    1. Wang L
    2. Chen KH
    3. Zhou M
    (2023) RCSB Protein Data Bank
    ID 7TAI. Structure of STEAP2 in complex with ligands.
    https://www.rcsb.org/structure/7TAI

References

    1. Emsley P
    2. Lohkamp B
    3. Scott WG
    4. Cowtan K
    (2010) Features and development of Coot
    Acta Crystallographica. Section D, Biological Crystallography 66:486–501.
    https://doi.org/10.1107/S0907444910007493

Article and author information

Author details

  1. Kehan Chen

    Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, United States
    Contribution
    Formal analysis, Investigation, Methodology, Writing – review and editing
    Contributed equally with
    Lie Wang
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0419-8360

  2. Lie Wang

    Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, United States
    Contribution
    Formal analysis, Investigation, Methodology, Writing – review and editing
    Contributed equally with
    Kehan Chen
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9406-5168

  3. Jiemin Shen

    Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, United States
    Contribution
    Investigation, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3977-0681

  4. Ah-Lim Tsai

    Division of Hematology-Oncology, Department of Internal Medicine, University of Texas-McGovern Medical School, Houston, United States
    Contribution
    Resources, Formal analysis, Funding acquisition, Methodology, Writing – review and editing
    Competing interests
    No competing interests declared

  5. Ming Zhou

    Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, United States
    Contribution
    Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing - original draft, Project administration, Writing – review and editing
    For correspondence
    mzhou@bcm.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7198-165X

  6. Gang Wu

    Division of Hematology-Oncology, Department of Internal Medicine, University of Texas-McGovern Medical School, Houston, United States
    Contribution
    Conceptualization, Resources, Data curation, Formal analysis, Supervision, Validation, Investigation, Methodology, Writing - original draft, Project administration, Writing – review and editing
    For correspondence
    gang.wu@uth.tmc.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6803-0853

Funding

National Institutes of Health (GM145416)

  • Ming Zhou

National Institutes of Health (DK122784)

  • Ming Zhou

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Version history

  1. Preprint posted:
  2. Sent for peer review:
  3. Reviewed Preprint version 1:
  4. Reviewed Preprint version 2:
  5. Version of Record published:

Cite all versions

You can cite all versions using the DOI https://doi.org/10.7554/eLife.88299. This DOI represents all versions, and will always resolve to the latest one.

Copyright

© 2023, Chen, Wang et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 714
    views
  • 102
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Kehan Chen
  2. Lie Wang
  3. Jiemin Shen
  4. Ah-Lim Tsai
  5. Ming Zhou
  6. Gang Wu
(2023)
Mechanism of stepwise electron transfer in six-transmembrane epithelial antigen of the prostate (STEAP) 1 and 2
eLife 12:RP88299.
https://doi.org/10.7554/eLife.88299.3

Share this article

https://doi.org/10.7554/eLife.88299

Categories and tags

Research organism

Further reading

    1. Biochemistry and Chemical Biology

    SLC35G1 is a highly chloride-sensitive transporter responsible for the basolateral membrane transport in intestinal citrate absorption

    Yoshihisa Mimura, Tomoya Yasujima ... Hiroaki Yuasa
    Short Report

    The intestinal absorption of essential nutrients, especially those not readily biosynthesized, is a critical physiological process for maintaining homeostasis. Numerous studies have indicated that intestinal absorption is mediated by various membrane transporters. Citrate, a crucial bioactive compound produced as an intermediate in the Krebs cycle, is absorbed in the small intestine through carrier-mediated systems because of its high hydrophilicity. While the luminal absorption of citrate is mediated by Na+-dicarboxylate cotransporter 1 (NaDC1/SLC13A2), the mechanism governing the release of the transported citrate into the bloodstream remains unknown. Here, we explored the transporters responsible for intestinal citrate absorption at the basolateral membrane, focusing on highly expressed orphan transporters in the small intestine as candidates. Consequently, SLC35G1, originally identified as a partner of stromal interaction molecule 1, a cell surface transmembrane glycoprotein, was found to play a role in the intestinal absorption of citrate at the basolateral membrane. Furthermore, our results revealed that SLC35G1-mediated citrate transport was diminished by chloride ions at physiologically relevant extracellular concentrations. This suggests that SLC35G1, to our best knowledge, is the first transporter identified to be extremely sensitive to chloride ions among those functioning on the basolateral membrane of intestinal epithelial cells. This study provides valuable insights into the intestinal absorption of citrate and significantly contributes to elucidating the poorly understood molecular basis of the intestinal absorption system.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease

    Reassessing the substrate specificities of the major Staphylococcus aureus peptidoglycan hydrolases lysostaphin and LytM

    Lina Antenucci, Salla Virtanen ... Perttu Permi
    Research Article

    Orchestrated action of peptidoglycan (PG) synthetases and hydrolases is vital for bacterial growth and viability. Although the function of several PG synthetases and hydrolases is well understood, the function, regulation, and mechanism of action of PG hydrolases characterised as lysostaphin-like endopeptidases have remained elusive. Many of these M23 family members can hydrolyse glycyl-glycine peptide bonds and show lytic activity against Staphylococcus aureus whose PG contains a pentaglycine bridge, but their exact substrate specificity and hydrolysed bonds are still vaguely determined. In this work, we have employed NMR spectroscopy to study both the substrate specificity and the bond cleavage of the bactericide lysostaphin and the S. aureus PG hydrolase LytM. Yet, we provide substrate-level evidence for the functional role of these enzymes. Indeed, our results show that the substrate specificities of these structurally highly homologous enzymes are similar, but unlike observed earlier both LytM and lysostaphin prefer the D-Ala-Gly cross-linked part of mature peptidoglycan. However, we show that while lysostaphin is genuinely a glycyl-glycine hydrolase, LytM can also act as a D-alanyl-glycine endopeptidase.

    1. Biochemistry and Chemical Biology
    2. Chromosomes and Gene Expression

    Human DCP1 is crucial for mRNA decapping and possesses paralog-specific gene regulating functions

    Ting-Wen Chen, Hsiao-Wei Liao ... Chung-Te Chang
    Research Article

    The mRNA 5'-cap structure removal by the decapping enzyme DCP2 is a critical step in gene regulation. While DCP2 is the catalytic subunit in the decapping complex, its activity is strongly enhanced by multiple factors, particularly DCP1, which is the major activator in yeast. However, the precise role of DCP1 in metazoans has yet to be fully elucidated. Moreover, in humans, the specific biological functions of the two DCP1 paralogs, DCP1a and DCP1b, remain largely unknown. To investigate the role of human DCP1, we generated cell lines that were deficient in DCP1a, DCP1b, or both to evaluate the importance of DCP1 in the decapping machinery. Our results highlight the importance of human DCP1 in decapping process and show that the EVH1 domain of DCP1 enhances the mRNA-binding affinity of DCP2. Transcriptome and metabolome analyses outline the distinct functions of DCP1a and DCP1b in human cells, regulating specific endogenous mRNA targets and biological processes. Overall, our findings provide insights into the molecular mechanism of human DCP1 in mRNA decapping and shed light on the distinct functions of its paralogs.